The safety of 'Levovir(clevudine)' is approved by the KFDA.
The safety of 'Levovir(clevudine)' is approved by the KFDA.
  • Healthkoreanews
  • 승인 2009.05.08 15:36
  • 댓글 0
이 기사를 공유합니다

The Central Pharmacist Committee of KFDA has hold a meeting of PMS committe on 7 May, and concluded that Levovir(clevudine), Bukwang Pharmacheuticals' drug for the treatment of HBV, has hardly any problem in its safety.

Clevudine was licensed to Pharmasset(U.S.A, drug maker) from Bukwang Pharmaceuticals, where the drug is marketed under the brand name 'Levovir'.

But because some South Korean patients receiving clevudine as prescribed therapy for hepatitis B have reported more serious myopathy than have patients in the Pharmasset clinical trials, Pharmasset decided on 20 April 2009 to voluntarily terminate its Phase III QUASH studies of clevudine for the treatment of chronic hepatitis B(HBV) infection.

And Bukwang Pharmmceuticals has temporarily stopped selling Levovir.

As a result of the KFDA's conclusion, Bukwang will restart selling Levovir sooner or later.<헬스코리아뉴스>

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

      편집자 추천 뉴스
      베스트 클릭
      오늘의 단신